PDCD1 and lung carcinoma: The combination of CBL-B-specific small molecule inhibitors with anti-PD-1/anti-LAG-3 antibody immunotherapies resulted in significant therapeutic efficacies in lung cancer models resistant to conventional immunotherapies.